|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2010-4-20
|
|
pubmed:abstractText |
On a voluntary basis therapeutic drug monitoring (TDM) was implemented in the ALL-BFM 2000 protocol for the three currently used asparaginase (ASNase) preparations (first line: native Escherichia coli ASNase; second line: pegylated ASNase and third line: Erwinia chrysanthemi ASNase).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1545-5017
|
|
pubmed:author |
|
|
pubmed:copyrightInfo |
Copyright 2010 Wiley-Liss, Inc.
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
54
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
952-8
|
|
pubmed:meshHeading |
pubmed-meshheading:20108339-Adolescent,
pubmed-meshheading:20108339-Antineoplastic Agents,
pubmed-meshheading:20108339-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20108339-Asparaginase,
pubmed-meshheading:20108339-Child,
pubmed-meshheading:20108339-Child, Preschool,
pubmed-meshheading:20108339-Clinical Trials as Topic,
pubmed-meshheading:20108339-Drug Hypersensitivity,
pubmed-meshheading:20108339-Drug Monitoring,
pubmed-meshheading:20108339-Escherichia coli,
pubmed-meshheading:20108339-Female,
pubmed-meshheading:20108339-Humans,
pubmed-meshheading:20108339-Infant,
pubmed-meshheading:20108339-Male,
pubmed-meshheading:20108339-Pectobacterium chrysanthemi,
pubmed-meshheading:20108339-Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Therapeutic drug monitoring of asparaginase in the ALL-BFM 2000 protocol between 2000 and 2007.
|
|
pubmed:affiliation |
Department of Paediatric Haematology and Oncology, University Hospital Muenster, Muenster, Germany.
|
|
pubmed:publicationType |
Journal Article,
Multicenter Study
|
